Newron Pharmaceuticals S.p.A. (SWX: NWRN)
Health Care · Pharmaceuticals · IT
CHF8.12
-22.37% today · -37.3% 1Y
Newron Pharmaceuticals S.p.A. (SWX: NWRN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $207.97M and employs 27 people.
Over the last twelve months the share price has lost 37.3%, trading between 7.61 and 31.85.
Tweenvest scores Newron Pharmaceuticals S.p.A. across four factors: quality 32/100, value 38/100, growth 76/100. Its strongest factor is growth.
NWRN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $207.97M
- Revenue (TTM)
- $11.90M
- P/E
- —
- EPS
- -1.46
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- CHF31.85
- 52-week low
- CHF7.61
- Avg volume (3M)
- —
- Shares outstanding
- 21.24M
- Employees
- 27
- Next earnings
- —
About Newron Pharmaceuticals S.p.A.
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.
- ISIN
- IT0004147952
- Founded
- 1999
- Listed since
- Dec 12, 2006
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Beta Drugs LimitedNSEI: BETA | $218.29M | Rs2,073.30 | -1.21% |
| Imexpharm CorporationHOSE: IMP | $216.92M | ₫36,600.00 | -0.81% |
| Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)CASE: RMDA | $211.63M | EGP5.45 | -5.55% |
| SCI Pharmtech, Inc.TWSE: 4119 | $208.59M | NT$55.60 | -1.94% |
| Huons Global Co., Ltd.KOSDAQ: A084110 | $204.40M | ₩22,550.00 | +5.87% |
| Savior Lifetec CorporationTPEX: 4167 | $203.48M | NT$19.55 | +0.77% |
| Sinphar Pharmaceutical Co.,Ltd.TWSE: 1734 | $203.07M | NT$32.10 | +0.31% |
| Alar Pharmaceuticals Inc.TPEX: 6785 | $198.59M | NT$94.70 | -4.15% |
Figures last refreshed Oct 4, 2026.